In summary, we identified four key components of EJW for treating AD through network pharmacology: iosgenin, baicalein, beta-sitosterol, and quercetin, and we screened ten core targets, including AKT1, IL6, VEGFA, TP53, CASP3, among others. This evidence concerns the gene TP53 and Alzheimer disease.